Potential side effects of GPNA, CB-839 or others could be reduced by lowering the dose and drug efficacy could be increased by co-treatment with UGCG inhibitors, because we assume that both inhibitors would work synergistically in the process of inhibiting breast cancer cell proliferation. This evidence concerns the gene UGCG and breast carcinoma.